Home » Archive by Category

News

Original content and news from BioSpace, Xconomy, Marketwire and other sources, specific to the region.

Solstice Biologics Names CEO With Boston VC Pedigree

June 9, 2014 – 5:10 pm | Edit Post

Venture capital veteran from Boston joining San Diego biotech as CEO.

Lou Tartaglia Leaves Third Rock to Run High-Drama RNAi Startup

June 9, 2014 – 10:03 am | Edit Post
Lou Tartaglia Leaves Third Rock to Run High-Drama RNAi Startup

[Updated 6/9/14, 3:55 pm. See below.] Solstice Biologics is announcing a new CEO today, and it’s a testament to the San Diego startup’s rollercoaster ride to say the news is one of the least dramatic…

[[Click headline to continue reading.]]

Sanford-Burnham displays research “art” at San Diego International Airport

June 9, 2014 – 8:54 am | Edit Post
Sanford-Burnham displays research “art” at San Diego International Airport

Sanford-Burnham’s research was recently unveiled as part of an art exhibit at the San Diego International Airport. The exhibit, sponsored by Biocom, the association for the Southern California life science community, and the San Diego International Airport Art Program, showcases microscopic research contributing to life-changing breakthroughs taking place in the Southern California region. The “Taking

Read More

Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race

June 9, 2014 – 12:00 am | Edit Post
Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race

Akebia Therapeutics and its investors had hit a crossroads familiar to many startup biotechs last year. Its lead drug, AKB-6548, a pill for the anemia people get when their kidneys are failing, had…

[[Click headline to continue reading.]]

Pfenex Inc. Aims for $74.8M IPO

June 8, 2014 – 4:07 pm | Edit Post

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

Pfenex Inc. Plans $74.8 M illion IPO

June 6, 2014 – 3:52 pm | Edit Post

Pfenex Inc., a spinoff of Dow Chemical Co., is the latest San Diego biotech to file for an initial public offering, looking to raise $74.8 million to fund its development of biosimilars.

New President, CFO at Celladon Says Co. Ripe to Expand Staff

June 6, 2014 – 3:07 pm | Edit Post

I chatted recently with Paul Cleveland, a veteran biotech finance guy who has recently been brought on as president and chief financial officer for the newly public gene therapy company Celladon Corp. Cleveland most recently was CFO of Aragon Pharmaceuticals Inc., a San Diego drugmaker sold to Johnson & Johnson last August for $1 billion.

Legislation Aims to Foster Investment in Biotech

June 6, 2014 – 2:30 pm | Edit Post

Biotech companies across California and the nation are facing critical issues raising capital. An extraordinary amount of time and money goes into uncovering the next scientific breakthrough; it is estimated that developing a single therapeutic can cos…

Post-IPO Biotechs Have News, But Big Pharma Drives the ASCO Boat

June 6, 2014 – 1:49 pm | Edit Post
Post-IPO Biotechs Have News, But Big Pharma Drives the ASCO Boat

As often happens, industry news from the annual American Society of Clinical Oncology (ASCO) meeting, which ended Wednesday in Chicago, was dominated this year by Big Pharma. It’s not…

[[Click headline to continue reading.]]

Sanford-Burnham grad students explore “The Bigger Picture”

June 6, 2014 – 6:00 am | Edit Post

Guest post by Sanford-Burnham graduate student, Matthew Tierney. This past May 21st through the 23rd, students and faculty of the Sanford-Burnham Graduate School of Biomedical Sciences met in Temecula, Calif., for their 5th annual program retreat. The meeting featured Drs. Sarah Hymowitz of Genentech and Paul Rejto of Pfizer as keynote speakers and included three

Read More